Table 1 Clinical characteristics of patients included in this study
From: ZEB1 promotes the immune escape of ovarian cancer through the MCSF-CCL18 axis
Mean Age | 41.75 ± 9.64 |
|---|---|
Mean Duration of Disease | 4.03 ± 2.11 |
Stage I | 17 (28.3%) |
Stage II | 18 (30.0%) |
Stage III | 12 (20.0%) |
Stage IV | 13 (21.7%) |
Serous Carcinoma | 42 (70.0%) |
Endometrioid Carcinoma | 13 (21.7%) |
Mucinous Carcinoma | 5 (8.3%) |
Grade II | 25 (41.7%) |
Lymph Node Metastasis | 38 (63.3%) |